Advertisement

Topics

Cynata to Present at the 19th Annual Rodman & Renshaw Global Investment Conference in New York

20:00 EDT 4 Sep 2017 | Globe Newswire

MELBOURNE, Australia, Sept. 05, 2017 (GLOBE NEWSWIRE) -- Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX:CYP), announced today it will be featured as a presenting company at the 19th Annual Rodman & Renshaw Global Investment Conference. The conference is being held on September 10-12, 2017 in New York City.

The Rodman & Renshaw conference is sponsored by H. C. Wainwright & Co., a leading Wall Street investment bank, with a strong reputation in life sciences. Over 2,000 institutional and other investors are expected to attend the conference, each with a significant interest in the life sciences sector.

Dr Ross Macdonald, Managing Director and CEO, will provide an overview of the Company and its unique Cymerus™ platform during the live presentation and will also be participating in one-on-one meetings with U.S. and international investors and potential partners who are registered to attend the conference. A copy of the presentation will be made available on Cynata’s website.

If you are an institutional investor, and would like to attend the Company’s presentation, please visit the Rodman & Renshaw website to register for the conference. Once your registration is confirmed, you will be prompted to log into the conference website to request a one-on-one meeting with the Company.

Event: 19th Annual Rodman & Renshaw Global Investment Conference
Date: September 11, 2017
Time: 3:00pm (US Eastern Time)
Location: Holmes II Room; Lotte New York Palace Hotel in New York City

About Cynata Therapeutics (ASX:CYP)
Cynata Therapeutics Limited (ASX:CYP) is an Australian clinical-stage stem cell and regenerative medicine company developing therapies based on its proprietary Cymerus™ stem cell technology platform. Cymerus overcomes critical issues in the production of therapeutic mesenchymal stem cells (MSCs) by enabling the economical manufacture of commercial-scale MSCs, independent of multi-donor limitations. Cymerus’ novel approach utilises induced pluripotent stem cells (iPSCs) derived from a single blood donation to generate mesenchymoangioblasts (MCAs), a precursor that is used to manufacture an unlimited number of therapeutic MSCs. Cynata’s unique “off-the-shelf” Cymerus platform has the potential to create a new standard in the development and manufacture of stem cell therapeutics.

CONTACTS:
Dr Ross Macdonald, CEO, 0412 119343, ross.macdonald@cynata.com
Daniel Paproth, Australia Media Contact, 0421 858 982, daniel.paproth@mcpartners.com.au  
Laura Bagby, U.S. Media Contact, 312-448-8098, lbagby@6degreespr.com

Primary Logo

NEXT ARTICLE

More From BioPortfolio on "Cynata to Present at the 19th Annual Rodman & Renshaw Global Investment Conference in New York"

Quick Search
Advertisement
 

Relevant Topic

Stem Cells
Track and monitor developments in stem cell research and commercial development.  Follow the tabs above to read the latest global news, research, clinical trials on stem cells and follow companies active in the stem cell industry.  BioPort...